Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
- 1 October 2002
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 85 (2-3) , 195-197
- https://doi.org/10.1016/s0167-5273(02)00182-1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Endothelial dysfunction in chronic heart failure: clinical implications and therapeutic optionsInternational Journal of Cardiology, 2001
- Endothelin antagonists for chronic heart failure: do they have a role?Published by Oxford University Press (OUP) ,2001
- The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failureInternational Journal of Cardiology, 2001
- Endothelin release: a marker for the severity of exercise-induced ischemiaInternational Journal of Cardiology, 2001
- The importance and complexity of neurohumeral over-activity in chronic heart failureInternational Journal of Cardiology, 2000
- The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1International Journal of Cardiology, 2000
- Prognostic value of plasma endothelin-1 in patients with chronic heart failureEuropean Heart Journal, 1997
- Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETBreceptorsJournal of Applied Physiology, 1996